TGFB1 and neoplasm: Potential resolutions for these challenges for CAR T cells include targeting multiple tumor antigens, engineered to secrete anti-tumor cytokines, ICI, and inhibitors for immunosuppressive cytokines (TGF-β1 and IL-4), increasing T cell expansion or persistence, and enhancing tumor infiltration [111].